A Phase 1/2, Open Label, Dose Escalation Study of Intravenous Administration of Single Agent NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Phase of Trial: Phase I/II
Latest Information Update: 25 Jun 2017
At a glance
- Drugs NEOD 001 (Primary)
- Indications Amyloidosis
- Focus Adverse reactions
- Sponsors Onclave Therapeutics; Prothena
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association.
- 28 Apr 2017 Results from the expansion phase (n=42), presented at the 69th Annual Meeting of the American Academy of Neurology.
- 19 Mar 2017 Status changed from active, no longer recruiting to completed, according to results presented at the 66th Annual Scientific Session of the American College of Cardiology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History